



CURRICULUM VITAE

Prof. Dr. Carsten Schwarz, M.D., born on October 17th 1969 in Berlin Germany

Head Division Cystic Fibrosis and CF Centre, Lung and Liver-Transplantation Program. Professor of Internal Medicine and Pneumology.

Postgraduate Education/Specialization/Training

- 2008 Medical specialist for Palliative Care, Lung Hospital Heckeshorn, Berlin.
- 2007 Medical specialist for Pneumology, Lung Hospital Heckeshorn, Berlin.
- 2006 Medical specialist for Internal Medicine, Lung Hospital Heckeshorn, Berlin.
- 1999 Medical License obtained, Berlin.
- 1999 Medical doctor, Humboldt University Berlin.

Leading Positions

- Since 2023 Member of the Academic Senate at HMU-University Potsdam
- Since 2023 Member of the Faculty Council at HMU-University Potsdam
- Since 2022 Professor of Internal Medicine and Pneumology HMU-University Potsdam
- Since 2022 Coordinator Research and Education at HMU-University Potsdam
- Since 2021 Head Division Cystic Fibrosis and CF Center Westbrandenburg, Campus Potsdam
- 2020-2023 Chairman of the Steering Committee of the Cystic Fibrosis AWMF-Guideline Lung disease in CF (S3): *Pseudomonas aeruginosa*
- 2020-2023 Board member ECFS
- Since 2020 Chairman Division CF of the German Pneumology Society (DGP)
- 2019-2022 Board Member FGM Germany
- Since 2018 ECFC Steering Committee board member
- Since 2018 Steering committee member Proteostasis, study 801-01
- Since 2018 Steering committee member Proteostasis, study 808-01
- Since 2018 Global PI for Vertex, study VX17 659-102
- Since 2017 Scientific board member NovaBiotics Ltd
- Since 2017 Steering committee member ASCENT international educational

	Program
Since 2017	Co-chairman of ECMM/ISHAM for Fungal Respiratory Infections in Cystic Fibrosis (Fri-CF)
Since 2017	Chairman/Coordinator ECFS Fungal Pathogens Working Group
2017	Guest Editor Mycopathologia (Special issue on fungi in CF)
Since 2014	Member of the European Cystic Fibrosis Conference Committee
Since 2013	Chairman of the steering Committee of the Cystic Fibrosis Guideline Lung disease in CF (S3), Modul 2: Chronic <i>Pseudomonas</i> Infection
2013-2021	Director Adult Cystic Fibrosis Centre Charité – Universitätsmedizin Berlin
Since 2012	Chairman Benchmarking Project Group Rare pathogens in patients with CF
Since 2012	Chairman Consortium of Aspergillus Categorization in CF (ACCF)
Since 2012	Member of ECMM/ISHAM for Fungal Respiratory Infections in Cystic Fibrosis (Fri-CF)
Since 2010	Chairman Physicians' Council of the German Cystic Fibrosis Foundation "Mukoviszidose e.V. – AGAM"
Since 2010	Member of Therapy Promotion and Quality Board (TFQ)
2010-2017	Medical advisor for CF nurses in Germany of the Mukoviszidose e.V. and chairman of the German Care guidelines 2010 and 2015
2010 – 2013	Group leader of the German Cystic Fibrosis Guideline (S3) Lung disease in CF, Modul 1: Diagnostic and Therapy after first detection of <i>Pseudomonas aeruginosa</i>
2008 – 2012	Group leader of Skin Cancer Guideline (S3)
Since 2008	Chairman "Network of fungi in patients with CF"
Since 2007	Head Lung-Transplantation Program and Endoscopy Unit Charité – Universitätsmedizin Berlin
2007 – 2013	Consultant (Cystic Fibrosis Centre) Charité – Universitätsmedizin Berlin
2005 – 2007	Consultant (Pneumology) Lung Hospital Heckeshorn

Active Congress Participation

- ERS European Respiratory Society Conference
- NACFC North American Cystic Fibrosis Conference
- ECFC European Cystic Fibrosis Conference
- ATS American Thorax Society Conference
- MECFCA Middle East Cystic Fibrosis Association Conference
- DGP Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin Kongress
- DMT Deutsche Mukoviszidose Tagung
- HAI Hauptstadtkongress für Anästhesie und Intensivmedizin
- GPP Gesellschaft für pädiatrische Pneumologie Kongress

Leading positions in medical conferences/meetings

2023

- Lecturer CF Experts, Vienna, Austria.

- President Thesis Tribunal, Bilbao, Spain.
- Member, lecturer DNWG, ECFS, Montpellier, France.
- Chairman CF Education Program ASCENT.
- Chairman CF Working Group at DGP, Düsseldorf, Germany.

2022

- Chairman ECFS Fungal Pathogens Working Group Meeting, Rotterdam, Netherlands.
- Chairman CF Working Group at DGP, Leipzig, Germany.
- Chairman Education Symposium DMT, Würzburg, Germany.
- Senior Lecturer Oslo, Norway.
- Senior Lecturer Copenhagen, Denmark.
- Senior Lecturer Masterclass, Stockholm, Sweden.
- Senior Lecturer Gothenburg, Sweden.
- Senior Lecturer Helsinki, Finland.

2021

- Chairman 20th Scientific Meeting, Montabaur, Germany.
- Chairman ECFS Fungal Pathogens Working Group Meeting, online.
- Chairman up-date CF, online.
- Chairman Education Symposium DMT, online.
- Chairman Meet the Expert, ECFC online.

2020

- Chairman ECFS Fungal Pathogens Working Group Meeting, online.
- Chairman up-date CF, online.
- Chairman Education Symposium DMT, online.
- Chairman Meet the Expert, ECFC online.

2019

- Chairman Session III, 19th Scientific Meeting, Montabaur
- Chairman of the ECFS Fungal Pathogens Working Group Meeting, Liverpool
- Chairman Satellite Symposium, Inhaled antibiotics, ECFC, Liverpool
- Senior Lecturer and Chairman European Young Investigator Meeting, Paris
- Chairman New therapies for CF, DGP/GPP, Munich

2018

- Chairman Education Program in CF Meeting, Amsterdam
- Chairman ECFS Fungal Pathogen Working Group Meeting, Belgrade
- Chairman Education Symposium DMT, Würzburg, Germany

2017

- Chairman Education Program in CF meeting, Zurich
- Chairman New inhaled antibiotics in CF, training for clinicians from UK, Sevilla
- Chairman International Pediatric Medical Endoscopy Training, Hamburg

2016

- Chairman Conference Fungi in Cystic Fibrosis, Waldthausen
- Chairman International Pediatric Medical Endoscopy Training, Basel
- Chairman International Medical Endoscopy Training in Thoracoscopy, Berlin
- Chairman Education Program in CF Meeting, Amsterdam
- Meet the expert, ECFC, Basel
- Chairman round table, ECFC, Basel

2015

- President of the German Cystic Fibrosis Conference, Würzburg
- Chairman International Pediatric Endoscopy Training Course, Berlin
- Chairman International Medical Endoscopy Training in Thoracoscopy, Berlin

Several scientific presentations/talks during ECFC, NACFC, ERS, DGP and DMT in the last 10 years.

Honors

Oskar Kuhn Health Award 2001 (Federal Ministry of Health)
Nomination and appreciation for the Berlin Health Award 2008
German Cystic Fibrosis Conference Poster Award 2011 (DMT)
German Cystic Fibrosis Conference Poster Award 2012 (DMT)
German Cystic Fibrosis Conference Poster award 2013 (DMT)
German Cystic Fibrosis Conference Poster award 2016 (DMT)
Nomination and appreciation for the Infectiology award 2012 and 2013
Infectiology Award, Gilead 2018

Grants

Novartis Grant	2012
Pharmaxis Grant	2013
Christiane Herzog Foundation Grant	2014
Robert Koch Institute Grant	2014
Novartis Grant	2015
Gilead Grant	2015
Basic Research Grant NACFC Foundation	2015
German Ministry of Education and Health (BMBF)	2016
Research Grant Horizon 2020	2017

1. Research Article

Schwarz C, Eschenhagen P, Schmidt H, Hohnstein T, Iwert C, Grehn C, Roehmel J, Steinke E, Stahl M, Lozza L, Tikhonova E, Rosati E, Stervbo U, Babel N, Mainz JG, Wisplinghoff H, Ebel F, Jia LJ, Blango MG, Hortschansky P, Brunke S, Hube B, Brakhage AA, Kniemeyer

O, Scheffold A, Bacher P. Antigen specificity and cross-reactivity drive functionally diverse anti-Aspergillus fumigatus T cell responses in cystic fibrosis.
J Clin Invest. 2023 Mar 1;133(5):e161593. doi: 10.1172/JCI161593.PMID: 36701198

Schwarz C. Clinical Relevance of Fungi in Cystic Fibrosis. Semin Respir Crit Care Med. 2023 Apr;44(2):252-259. doi: 10.1055/s-0042-1759882. Epub 2023 Feb 6.

Mainz JG, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, Smaczny C, Barucha A, Bechinger L, Duckstein F, Kurzidim L, Eschenhagen P, Caley L, Peckham D, **Schwarz C.** Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score.
Front Pharmacol. 2022 Jun 3;13:877118. doi: 10.3389/fphar.2022.877118. eCollection 2022.PMID: 35721187

Lackner M, Rössler A, Volland A, Stadtmüller MN, Müllauer B, Banki Z, Ströhle J, Luttick A, Fenner J, Sarg B, Kremser L, Tone P, Stoiber H, von Laer D, Wolff T, **Schwarz C**, Nagl M. N-chlorotaurine is highly active against respiratory viruses including SARS-CoV-2 (COVID-19) in vitro. Emerg Microbes Infect. 2022 Dec;11(1):1293-1307. doi: 10.1080/22221751.2022.2065932.PMID: 35418279

Martin-Souto L, Antoran A, Areitio M, Aparicio-Fernandez L, Martín-Gómez MT, Fernandez R, Astigarraga E, Barreda-Gómez G, **Schwarz C**, Rickerts V, Hernando FL, Rementeria A, Buldain I, Ramirez-Garcia A. Dot Immunobinding Assay for the Rapid Serodetection of Scedosporium/Lomentospora in Cystic Fibrosis Patients.
J Fungi (Basel). 2023 Jan 24;9(2):158. doi: 10.3390/jof9020158.PMID: 36836272

Fischer R, **Schwarz C**, Weiser R, Mahenthiralingam E, Smerud K, Meland N, Flaten H, Rye PD. Evaluating the alginate oligosaccharide (OligoG) as a therapy for Burkholderia cepacia complex cystic fibrosis lung infection.
J Cyst Fibros. 2022 Sep;21(5):821-829. doi: 10.1016/j.jcf.2022.01.003. Epub 2022 Jan 24.PMID: 35086790

Wetzstein N, Diricks M, Kohl TA, Wichelhaus TA, Andres S, Paulowski L, **Schwarz C**, Lewin A, Kehrmann J, Kahl BC, Dichtl K, Hügel C, Eickmeier O, Smaczny C, Schmidt A, Zimmermann S, Nährlich L, Hafkemeyer S, Niemann S, Maurer FP, Hogardt M. Molecular Epidemiology of Mycobacterium abscessus Isolates Recovered from German Cystic Fibrosis Patients. Microbiol Spectr. 2022 Aug 31;10(4):e0171422. doi: 10.1128/spectrum.01714-22. Epub 2022 Aug 8.PMID: 35938728

Hanafin PO, Sermet-Gaudelus I, Griese M, Kappler M, Ellemunter H, **Schwarz C**, Wilson J, Tan M, Velkov T, Rao GG, Schneider-Futschik EK. Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis.
Front Pharmacol. 2021 Aug 2;12:577263. doi: 10.3389/fphar.2021.577263. eCollection 2021.PMID: 34408649

Schwarz C, Taccetti G, Burgel PR, Mulrennan S Tobramycin safety and efficacy review article. . Respir Med. 2022 Apr-May;195:106778. doi: 10.1016/j.rmed.2022.106778. Epub 2022 Feb 25.PMID: 35249787

Schwarz C, Procaccianti C, Costa L, Brini R, Friend R, Caivano G, Sadafi H, Mussche C, Schwenck N, Hahn M, Murgia X, Bianco F. Differential Performance and Lung Deposition of Levofloxacin with Different Nebulisers Used in Cystic Fibrosis. *Int J Mol Sci*. 2022 Aug 24;23(17):9597. doi: 10.3390/ijms23179597.PMID: 36076992

Schwarz C, Eschenhagen P, Bouchara JP. Emerging Fungal Threats in Cystic Fibrosis. *Mycopathologia*. 2021 Oct;186(5):639-653. doi: 10.1007/s11046-021-00574-w. Epub 2021 Jul 28.PMID: 34319568

Hong G, Desai S, Moss RB, Eschenhagen P, Quon BS, **Schwarz C**. Clinician variability in the diagnosis and treatment of aspergillus fumigatus-related conditions in cystic fibrosis: An international survey. *J Cyst Fibros*. 2022 Jan;21(1):136-142. doi: 10.1016/j.jcf.2021.07.008. Epub 2021 Jul 29.PMID: 34332906

Li BCM, Huh SM, Prieto MD, Hong G, **Schwarz C**, Moss RB, Quon BS. J Biomarkers for the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis: A Systematic Review and Meta-Analysis. *Allergy Clin Immunol Pract*. 2021 May;9(5):1909-1930.e4. doi: 10.1016/j.jaip.2020.12.064. Epub 2021 Jan 14.

Benden C, **Schwarz C**. CFTR Modulator Therapy and Its Impact on Lung Transplantation in Cystic Fibrosis. *Pulm Ther*. 2021 Dec;7(2):377-393. doi: 10.1007/s41030-021-00170-9. Epub 2021 Aug 18.PMID: 34406641

Schwarz C, Procaccianti, Mignot B, et al. Deposition of inhaled Levofloxacin in Cystic Fibrosis Lungs Assessed by Functional Respiratory Imaging. *Pharmaceutics* 13(12):2051. DOI.org/10.3390/pharmaceutics13122051.

Schwarz C, Eschenhagen P, Schütte H, Sparke C, Jagdhuhn M, Mainz JG. Cystische Fibrose: Innovative Arzneimittel verlängern Lebenserwartung. *Dtsch Arztebl* 2021; 118(50): 26; DOI: 10.3238/PersPneumo.2021.12.17.06.

Lewin A, Kamal E, Semmler T, **Schwarz C**. Genetic diversification of persistent Mycobacterium abscessus within cystic fibrosis patients. *Virulence* 12(1):2415-2429. DOI:10.1080/21505594.2021.1959808.

Grehn C, Dittrich AM, Wosniok J, Holz F, Hafkemeyer S, Naehrlich L, **Schwarz C**. Risk factors for cystic fibrosis arthropathy: Data from the German cysticfibrosis registry. Registry working group of the German CF Registry. *J Cyst Fibros*. 2021 May 22:S1569-1993(21)00130-2. doi: 10.1016/j.jcf.2021.05.003.

Schwarz C, Grehn C, Temming S, Holz F, Eschenhagen P. Clinical impact of levofloxacin inhalation solution in cystic fibrosis patients in a real-world setting. *J Cyst Fibros*. 2021 Jun 4:S1569-1993(21)00051-5. doi: 10.1016/j.jcf.2021.03.002.

Grehn C, Eschenhagen P, Temming S, Duesberg U, Neumann K, **Schwarz C**. Frequent Pet Contact as Risk Factor for Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis. *Front Cell Infect Microbiol*. 2021 Jan 11;10:601821. doi: 10.3389/fcimb.2020.601821. eCollection 2020.

Clinical impact of levofloxacin inhalation solution in cystic fibrosis patients in a real-world setting. **Schwarz C**, Grehn C, Temming S, Holz F, Eschenhagen P. *J Cyst Fibros*. 2021 Jun 4;S1569-1993(21)00051-5. doi: 10.1016/j.jcf.2021.03.002. Online ahead of print.

Frequent Pet Contact as Risk Factor for Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis. Grehn C, Eschenhagen P, Temming S, Duesberg U, Neumann K, **Schwarz C**. *Front Cell Infect Microbiol*. 2021 Jan 11;10:601821. doi: 10.3389/fcimb.2020.601821. eCollection 2020.

[Many patients with cystic fibrosis have a better quality of life now]. Eschenhagen P, **Schwarz C**. *MMW Fortschr Med*. 2021 Mar;163(Suppl 1):74-81. doi: 10.1007/s15006-021-9804-z.

Prospective Evaluation of Aspergillus fumigatus-Specific IgG in Patients With Cystic Fibrosis. Eschenhagen P, Grehn C, **Schwarz C**. *Front Cell Infect Microbiol*. 2021 Jan 22;10:602836. doi: 10.3389/fcimb.2020.602836. eCollection 2020.

Urban Life as Risk Factor for Aspergillosis. Grehn C, Eschenhagen P, Temming S, Duesberg U, Neumann K, **Schwarz C**. *Front Cell Infect Microbiol*. 2020 Nov 2;10:601834. doi: 10.3389/fcimb.2020.601834. eCollection 2020.

Biomarkers for the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis: A Systematic Review and Meta-Analysis. Li BCM, Huh SM, Prieto MD, Hong G, **Schwarz C**, Moss RB, Quon BS. *J Allergy Clin Immunol Pract*. 2021 May;9(5):1909-1930.e4. doi: 10.1016/j.jaip.2020.12.064. Epub 2021 Jan 14.

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events. **Schwarz C**, Sutharsan S, Epaud R, Klingsberg RC, Fischer R, Rowe SM, Audhya PK, Ahluwalia N, You X, Ferro TJ, Duncan ME, Bruinsma BG. *J Cyst Fibros*. 2021 Mar;20(2):228-233. doi: 10.1016/j.jcf.2020.06.001. Epub 2020 Jun 23. PMID: 32586736

[Therapy of cystic fibrosis - new drugs give hope]. Eschenhagen P, **Schwarz C**. *Dtsch Med Wochenschr*. 2020 Oct;145(20):1486-1489. doi: 10.1055/a-1140-3937. Epub 2020 Oct 6.

Risk factors for respiratory Aspergillus fumigatus in German Cystic Fibrosis patients and impact on lung function. Duesberg U, Wosniok J, Naehrlich L, Eschenhagen P, **Schwarz C**. *Sci Rep*. 2020 Nov 4;10(1):18999. doi: 10.1038/s41598-020-75886-w.

[Patients with cystic fibrosis become adults: Treatment hopes and disappointments]. Eschenhagen P, **Schwarz C**. *Internist (Berl)*. 2019 Jan;60(1):98-108. doi: 10.1007/s00108-018-0536-9.

[Cystic fibrosis: A new disease pattern in adult medicine].

Staab D, **Schwarz C**. Internist (Berl). 2018 Nov;59(11):1138-1145. doi: 10.1007/s00108-018-0498-y.

Roehmel J, Brandt C, Kallinich T, Staab D, **Schwarz C**. Clinical manifestation and risk factors for arthropathy in cystic fibrosis. Respiratory Medicine. 1/2019,147-66,(147).

Schwarz C, Brandt C, Melichar V, Runge C, Heuer E, Sahly H, et al. Combined antifungal therapy is superior to monotherapy in pulmonary scedosporiosis in cystic fibrosis. Journal of Cystic Fibrosis. 3/2019,227-232,(18).

Schwarz C, Brandt C, Whitaker P, Sutharsan S, Skopnik H, Gartner S, Smazny C, Röhmel JF. Invasive Pulmonary Fungal Infections in Cystic Fibrosis. Mycopathologia. 1/2018,33-43,(183).

Schwarz C, Bouchara J-P, Buzina W, Chrenkova V, Dmeńska H, la Pedrosa de EGG, et al. Organization of Patient Management and Fungal Epidemiology in Cystic Fibrosis. Mycopathologia. 2/2018,7–19,(183).

Schwarz C, Hartl D, Eickmeier O, Hector A, Benden C, Durieu I, et al. Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis. Mycopathologia. 2/2018,21-32,(183).

Staab D, **Schwarz C**. Cystic fibrosis: A new disease pattern in adult medicine. Internist. 9/2018,1138–45,(59).

Schwarz C, Schulte-Hubbert B, Bend J, Abele-Horn M, Baumann I, Bremer W, Brunsmann F, Dieninghoff D, Eickmeier O, Ellemunter H, Fischer R, Grosse-Onnebrink J, Hammermann J, Hebestreit H, Hogardt M, Hügel C, Hug M, Illing S, Jung A, Kahl B, Koitschev A, Mahlberg R, Mainz JG, Mattner F, Mehl A, Möller A, Muche-Borowski C, Nüßlein T, Puderbach M, Renner S, Rietschel E, Ringshausen FC, Schmidt S, Sedlacek L, Sitter H, Smaczny C, Tümmler B, Vonberg R, Wielpütz MO, Wilkens H, Wollschläger B, Zerlik J, Düesberg U, van Koningsbruggen-Rietschel S. CF Lung Disease – a German S3 Guideline: Modul 2: Diagnostics and Treatment in Chronic Infection with Pseudomonas aeruginosa. Pneumologie. 5/2018, 347-392,(72).

Schwarz C, Müller T, Lau S, Parasher K, Staab D, Wahn U. Mepolizumab - a novel option for the treatment of hypereosinophilic syndrome in childhood. Pediatric Allergy and Immunology. 2/2018,28-33,(29).

Brandt C, Roehmel J, Rickerts V, Melichar V, Niemann N, **Schwarz C**. Aspergillus Bronchitis in Patients with Cystic Fibrosis. Mycopathologia. 2/2018,45-9,(16).

Schwarz C. Zystische Fibrose: Mukoviszidose ist längst keine Kinderkrankheit mehr. Deutsches Ärzteblatt. 9/2017,14-20,(144).

Schwarz C, Brandt C, Antweiler E, Krannich A, Staab D, Schmitt-Grohé S, Fischer R, Hartl D, Thronicke A, Tintelnot K. Prospective multicenter German study on pulmonary colonization with Scedosporium /Lomentospora species in cystic fibrosis: Epidemiology and new association factors. PLoS One. 2/2017,1-13,(12).

Brandt C, Thronicke A, Roehmel JF, Krannich A, Staab D, **Schwarz C**. Impact of Long-Term Tiotropium Bromide Therapy on Annual Lung Function Decline in Adult Patients with Cystic Fibrosis. PLoS One. 6/2016,1-11,(28).

Thronicke A, Heger N, Antweiler E, Krannich A, Roehmel J, Brandt C, Staab D, Tintelnot K, **Schwarz C**. Allergic bronchopulmonary aspergillosis is associated with pet ownership in Cystic Fibrosis. Pediatric Allergy and Immunology. 5/2016,597-603,(27).

Schwarz C. Palliative Care in der Lungentransplantation. Der Pneumologe. 3/2016,113-117,(13).

Schwarz C, Staab D. Cystic fibrosis and associated complications. Internist (Berl). 3/2015, 263-74,(56).

Steinkamp G, Stahl K, Ellemunter H, Heuer E, van Koningsbruggen-Rietschel S, Busche M, Bremer W, **Schwarz C**. Cystic fibrosis (CF) care through the patients' eyes - a nationwide survey on experience and satisfaction with services using a disease-specific questionnaire. Patient Experience Working Group. Respiratory Medicine. 1/2015,79-87,(109).

Stahl K, Steinkamp G, Ullrich G, Schulz W, van Koningsbruggen-Rietschel S, Heuer HE, Ellemunter H, **Schwarz C**. Patient experience in cystic fibrosis care: Development of a disease-specific questionnaire. Chronic Illness. 6/2015,108-25,(11).

Schwarz C, Schönfeld N, Bittner RC, Mairinger T, Rüssmann H, Bauer TT, Kaiser D, Loddenkemper R. Value of flexible bronchoscopy in the pre-operative work-up of solitary pulmonary nodules. European Respiratory Journal. 1/2013,177-82,(41).

Schwarz C. Arzneimitteltherapie der Zystischen Fibrose. Arzneimitteltherapie. 4/2013,80-88,(31).

Schildmann J, **Schwarz C**, Schildmann E, Klambeck A, Ortwein H, Vollmann J. "Truth at the bedside". Deutsch Medizinische Wochenschrift. 4/2011,757-61,(136). (geteilte Erstautorenschaft)

Schwarz C und Schönfeld N. Diagnostische Pleuroskopie. Atemweges- und Lungenkrankheiten. 10/2006,395-402,(32).

Schwarz C, Lübbert H, Rahn W, Schönfeld N, Serke M, Loddenkemper R. Medical thoracoscopy: hormone receptor content in pleural metastases due to breast cancer. European Respiratory Journal. 11/2004,728-30,(24).

Brunklaus A, Herrmann E, Klambeck A, **Schwarz C**. Introduction of breaking bad news courses at the Humboldt University Medical School Berlin. Medizinische Ausbildung. 11/2002,97-100,(19).

Schildmann J, Brunklaus A, Herrmann E, Klambeck A, Ortwein H, **Schwarz C**. Evaluation of a 'breaking bad news' course at the Charité, Berlin. Medical Education. 8/2001, 806-7,(35).

Mutation on *lysX* from *Mycobacterium avium hominissuis* impacts the host-pathogen interaction and virulence phenotype. Kirubakar G, Schäfer H, Rickerts V, **Schwarz C**, Lewin A. *Virulence*. 2020 Dec;11(1):132-144. doi: 10.1080/21505594.2020.1713690.

Roehmel JF, Specht P, Staab D, **Schwarz C**, Salama A, Mayer B. Risk of piperacillin-induced hemolytic anemia in patients with cystic fibrosis and antipseudomonal treatment: a prospective observational study. *Transfusion*. 11/2019,1-9,(59).

van Koningsbruggen-Rietschel S, Conrath K, Fischer R, Sutharsan S, Kempa A, Gleiber W, **Schwarz C**, Hector A, Van Osselaer N, Pano A, Corveleyn S, Bwirire D, Santermans E, Muller K, Bellaire S, Van de Steen O. GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN). *Journal of Cystic Fibrosis*. 10/2019,1569-93(19).

Severe infections of Panton-Valentine leukocidin positive *Staphylococcus aureus* in children. Hoppe PA, Holzhauer S, Lala B, Bühner C, Gratopp A, Hanitsch LG, Humme D, Kieslich M, Kallinich T, Lau S, Leistner R, Niebank M, Pokrywka A, Ringe H, Schaper AS, Schröder JT, **Schwarz C**, Staab D, Stegemann MS, Thee S, Varnholt V, von Bernuth H, Weber-Carstens S, Wendt A, Krüger R. *Medicine (Baltimore)*. 9/2019,98(38).

Dordevic A, Genger M, **Schwarz C**, Cuspidi C, Tahirovic E, Pieske B, Dungen HD, Tadic M. Biatrial Remodeling in Patients with Cystic Fibrosis Running Title: Atrial Function in Cystic Fibrosis. *Journal of Clinical Medicine*. 7/2019,1-10(8).

Drevinek P, Pressler T, Cipolli M, De Boeck K, **Schwarz C**, Bouisset F, Boff M, Henig N, Paquette-Lamontagne N, Montgomery S, Perquin J, Tomkinson N, den Hollander W, Elborn JS. Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis. *Journal of Cystic Fibrosis*. 6/2019,1-8(7).

Ruangkiattikul N, Rys D, Abdissa K, Rohde M, Semmler T, Tegtmeyer PK, Kalinke U, **Schwarz C**, Lewin A, Goethe R. Type I interferon induced by TLR2-TLR4-MyD88-TRIF-IRF3 controls *Mycobacterium abscessus* subsp. *abscessus* persistence in murine macrophages via nitric oxide. *International Journal of Medical Microbiology*. 7/2019,307-18(5).

Bacher P, Hohnstein T, Beerbaum E, Röcker M, Blango MG, Kaufmann S, Roehmel J, Eschenhagen P, Grehn C, Seidel K, Rickerts V, Lozza L, Stervbo U, Nienen M, Babel N, Milleck J, Assenmacher M, Cornely OA, Ziegler M, Wisplinghoff H, Heine G, Worm M, Siegmund B, Maul J, Creutz P, Tabeling C, Ruwwe-Gloesenkamp C, Sander LE, Knosalla C, Brunke S, Hube B, Kniemeyer O, Brakhage AA, **Schwarz C**, and Scheffold A. Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against *Candida albicans*. *Cell*. 3/2019,1340-55(6).

Shoulah SA, Oschmann AM, Selim A, Semmler T, **Schwarz C**, Kamal E, Hamouda F, Galila E, Bitter W, Lewin A. Environmental *Mycobacterium avium* subsp. *hominissuis* have a higher probability to act as a recipient in conjugation than clinical strains. *Plasmid*. 1/2018,28-35(95).

Scholz O, Denecke T, Böttcher J, **Schwarz C**, Mentzel HJ, Streitparth F, Maurer MH, Pfeil A, Huppertz A, Mehl A, Staab D, Hamm B, Renz DM. MRI of cystic fibrosis lung manifestations: sequence evaluation and clinical outcome analysis. Clinical Radiology. 3/2017,754-63(9).

Bacher P, Heinrich F, Stervbo U, Nienen M, Vahldieck M, Iwert C, Vogt K, Kollet J, Babel N, Sawitzki B, **Schwarz C**, Bereswill S, Heimesaat MM, Heine G, Gadermaier G, Asam C, Assenmacher M, Kniemeyer O, Brakhage AA, Ferreira F, Wallner M, Worm M, Scheffold A. Regulatory T Cell Specificity Directs Tolerance versus Allergy against Aeroantigens in Humans. Cell. 1/2016,1076-78(4).

Steinkamp G, Ellemunter H, **Schwarz C**, Stahl K. Different approaches to evaluate patient experience and satisfaction in CF centres. Journal of Cystic Fibrosis. 9/2015,19-20(5).

ECORN-CF Study Group. Erratum to "Practical guidelines: lung transplantation in patients with cystic fibrosis". Hirche TO, Knoop C, Hebestreit H, Shimmin D, Solé A, Elborn JS, Ellemunter H, Aurora P, Hogardt M, Wagner TO. Pulmonary Medicine. 1/2015,1-22(5).

Sedlacek L, Graf B, **Schwarz C**, Albert F, Peter S, Würstl B, Wagner S, Klotz M, Becker A, Haase G, Laniado G, Kahl B, Suerbaum S, Seibold M, Tintelnot K. Prevalence of Scedosporium species and Lomentospora prolificans in patients with cystic fibrosis in a multicenter trial by use of a selective medium. Journal of Cystic Fibrosis. 3/2015,237-41(14).

Renz DM, Scholz O, Böttcher J, Maurer MH, Denecke T, **Schwarz C**, Pfeil A, Streitparth F, Huppertz A, Mehl A, Poellinger A, Staab D, Hamm B, Mentzel HJ. Comparison between magnetic resonance imaging and computed tomography of the lung in patients with cystic fibrosis with regard to clinical, laboratory, and pulmonary functional parameters. Investigational Radiology. 10/2015,733-42(10).

Kurzdin L, **Schwarz C**, Schönfeld N, Barker M. Non-CF-Bronchiektasie im Kindes- und Erwachsenenalter. Der Pneumologe, 3/2014,110-19(2).

Roehmel JF, **Schwarz C**, Mehl A, Stock P, Staab D. Hypersensitivity to antibiotics in patients with cystic fibrosis. Journal of Cystic Fibrosis. 3/2014,205-11(2).

Bernhardt A, Sedlacek L, Wagner S, **Schwarz C**, Würstl B, Tintelnot K. Multilocus sequence typing of Scedosporium apiospermum and Pseudallescheria boydii isolates from cystic fibrosis patients. Journal of Cystic Fibrosis. 12/2013,592-8(6).

Assael BM, Pressler T, Bilton D, Fayon M, Fischer R, Chiron R, LaRosa M, Knoop C, McElvaney N, Lewis SA, Bresnik M, Montgomery AB, Oermann CM; **AZLI Active Comparator Study Group**. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. Journal of Cystic Fibrosis. 3/2013,130-40(2).

von der Hardt H, **Schwarz C**, Ullrich G. Adults with cystic fibrosis. It's not just about longevity. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 4/2012,558-67(4).

Schönfeld N, **Schwarz C**, Kollmeier J, Blum T, Bauer TT, Ott S. Narrow band imaging (NBI) during medical thoracoscopy: first impressions. Journal of Occupational Medicine and Toxicology. 8/2009,24-28(4).

Schildmann J, Herrmann E, Klambeck A, Ortwein H, **Schwarz C**, Vollmann J. "Truth at the bedside"--continuing medical education and breaking bad news. Zeitschrift für Ärztliche Fortbildung und Qualitätssicherung. 7/2005,443(7).

Herrmann E, Ortwein H, Klambeck A, **Schwarz C**, Schildmann J. "Wahrheit am Krankenbett" – ärztliche Fortbildungsveranstaltung zum Überbringen von schlechten Nachrichten: Kurskonzept und erste Evaluationsergebnisse. Zeitschrift für Palliativmedizin. 3/2005,6-68(1).

2. Case Reports

Roehmel JF, Tintelnot K, Bernhardt A, Seibold M, Staab D, **Schwarz C** *Arxula adenivorans* causing invasive pulmonary mycosis and fungaemia in cystic fibrosis. Lancet. 4/2015,1476(9976).

Schwarz C, Usemann J, Stephan V, Kaiser D, Rothe K, Rückert JC, Neudecker J. Bilateral pneumothorax following a blunt trachea trauma. Respiratory Medicine Case Reports. 9/ 2013,56-9(10).

Schwarz C, Bittner R, Kirsch A, Loddenkemper C, Mairinger T, Schönfeld N, Serke M, Loddenkemper R. A 62-year-old woman with bilateral pleural effusions and pulmonary infiltrates caused by extramedullary hematopoiesis. Respiration. 1/2009,110-3(1).

Meinus C, **Schwarz C**, Mayer B, Roehmel JF. Piperacillin-induced mild haemolytic anaemia in a 44-year-old patient with cystic fibrosis. British Medical Journal of Case Reports. 10/ 2016,1-3(1).

3. Reviews

Schwarz C, Martin-Souto L, Mainz JG, Romanoeská E, Ramirez-Garcia A, Eschenhagen P. Respiratory fungal infections in Cystic Fibrosis: Diagnostic and therapeutic challenges. In press 2023.

Schwarz C. Fungi in Cystic Fibrosis. SRCCM 2023.

Eschenhagen P, **Schwarz C**. Patients with cystic fibrosis become adults: Treatment hopes and disappointments. Internist (Berl). 1/2019,98-108(1).

Staab D, **Schwarz C**. Cystic fibrosis: A new disease pattern in adult medicine. Internist (Berl). 11,2018,1138-1145(11).

Schwarz C., Vandeputte P., Rougeron A., Giraud, S. et al. Developing collaborative works for faster progress on fungal respiratory infections in cystic fibrosis. Medical Mycology. 3/2017,1-42(5).

Schwarz C. Colobreathe for the treatment of cystic fibrosis-associated pulmonary infections. Pulmonary therapy. 11/2015,19-30(1).

Scheffold A, **Schwarz C**, Bacher P. Fungus-Specific CD4 T Cells as Specific Sensors for Identification of Pulmonary Fungal Infections. Mycopathologia. 2/2018,213-26(1).

Singh A, Ralhan A, **Schwarz C**, Hartl D, Hector A. Fungal Pathogens in CF Airways: Leave or Treat? Mycopathologia. 8/2017,21-32(1).

Ramirez-Garcia A., Pellon A, **Schwarz C.**, et al.. Scedosporium and Lomentospora: an updated overview of underrated opportunist. Medical Mycology. 4/2018,102-125(56).

Schönfeld N, Temme T, **Schwarz C**, Serke M, Ott S. Modern endoscopic procedures for diseases of the respiratory tract. Deutsche Medizinische Wochenschrift. 12/2007,2633-6(49).

4. Editorials/Comments

Chaparro C, Hopkins PM, **Schwarz C**. Long needed guidelines: Referral to transplant for cystic fibrosis patients. Journal of Cystic Fibrosis. 5/2019,305-6(3).

Schwarz C, Hartl D. Cystic fibrosis in Europe: patients live longer but are we ready? European Respiratory Journal. 7/2015,11-2(1).

5. Book Chapters

Schwarz C. Hodson and Geddes. Fungal diseases in CF. 2023.

Schwarz C and Knoop C. ECFS Book: The 2nd Edition. Living longer with CF: The increasing complexity of CF-related problems: Pulmonary complications. 6/2015. ISBN 9783000497547.

Schwarz C, Staab D. Pediatric Lung Transplantation. Section V: Psychosocial Aspects. End of Life Care - pre transplant and post transplant. ISHLT Monograph 2013,(7).

Update Mukoviszidose:

Band 6 Cystische Fibrose und andere seltene Lungenerkrankungen. Wagner TOF et al. Thieme 2013. ISBN 9783131769817.

Update Mukoviszidose: Band 5 Lungentransplantation. Wagner TOF et al. Thieme 2012. ISBN 9783131723611

Education program skin cancer screening (Fortbildungsprogramm Hautkrebs-Screening). Deutscher Ärzte-Verlag 2008.

C. Schwarz und T. Bauer Klinische Infektionen: Infektionen der Pleura. Urban und Fischer Elsevier Verlag 2007.

Endoscopy (Endoskopieassistenz). Gottschlak et al. 2009. Thieme ISBN 9783131530912.

Primary Immunodeficiency (Primäre Immundefekte). Wahn V et al. 2013. Marseille. ISBN 3886161455.

Potsdam, 8.3.2023

A handwritten signature in black ink, appearing to be 'M. Wahn', enclosed within a thin black rectangular border.